Search results
...0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor... Advanced Merkel Cell Carcinoma...
Morningstar· 6 days ago("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy and Kintara ...
Cryoablation: Purpose and what to expect
Medical News Today· 3 days agoCryoablation involves applying extremely cold gas or liquid to an area of cancerous or abnormal tissue. The treatment freezes and destroys the cells....
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days ago(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics..
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Zacks via Yahoo Finance· 5 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 7 days agoPromising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of patients who completed the Induction ...
...Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination... Treatment of Colon Cancer...
The Grass Valley Union· 6 days agoThe...
Molecular Templates reports progress in cancer therapy trials By Investing.com
Investing.com· 6 days agoMolecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company, has announced...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 6 days agoThe study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy...
...Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma...
Digital Journal· 6 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Case Study: Patient with Rare Breast Cancer Has Surprising Response to NAC
MedPage Today· 4 days ago"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey ...